First Trust Advisors LP Seagen Inc. Transaction History

First Trust Advisors LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$191.51 - $216.16 $21.1 Million - $23.9 Million	-110,419 Reduced 21.63%	400,164 $84.9 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $2.78 Million - $3.05 Million	14,792 Added 2.98%	510,583 $98.3 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $5.73 Million - $9.12 Million	44,931 Added 9.97%	495,791 $100 Million
Q4 2022 Feb 09, 2023	SELL	$117.37 - $139.17 $8.32 Million - $9.86 Million	-70,866 Reduced 13.58%	450,860 $57.9 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $17.1 Million - $22.8 Million	126,602 Added 32.04%	521,726 $71.4 Million

Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $10.4 Million - $17.2 Million	-95,901 Reduced 19.53%	395,124 $69.9 Million
Q1 2022 May 13, 2022	SELL	$119.61 - $157.85 $13.9 Million - $18.4 Million	-116,390 Reduced 19.16%	491,025 $70.7 Million
Q4 2021 Feb 08, 2022	BUY	$142.57 - $190.86 $3.32 Million - $4.44 Million	23,256 Added 3.98%	607,415 $93.9 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $2.39 Million - $2.85 Million	16,765 Added 2.95%	584,159 $99.2 Million
Q2 2021 Oct 12, 2021	SELL	$135.08 - $161.1 $158,043 - $188,487	-1,170 Reduced 0.21%	567,394 $89.6 Million
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $8.86 Million - $10.6 Million	65,618 Added 13.05%	568,564 $89.8 Million
Q1 2021 May 14, 2021	SELL	$137.51 - $190.8 $8.22 Million - $11.4 Million	-59,813 Reduced 10.63%	502,946 $69.8 Million
Q4 2020 Feb 02, 2021	BUY	$164.63 - $211.93 $92.6 Million - $119 Million	562,759 New	562,759 $98.6 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.